Orlistat: a review of its use in the management of obesity.

Article Details

Citation

Copy to clipboard

Henness S, Perry CM

Orlistat: a review of its use in the management of obesity.

Drugs. 2006;66(12):1625-56.

PubMed ID

16956313 [ View in PubMed

]

Abstract

Orlistat (Xenical) is a reversible inhibitor of gastric and pancreatic lipases. In conjunction with a hypocaloric diet and moderate exercise, orlistat is an effective drug for use in the management of obesity in adults with or without comorbidities. Recent data have shown that orlistat is also effective as a component of weight management strategies in obese adolescents. In addition to its well established efficacy in achieving modest weight loss, orlistat has been shown to improve glycaemic parameters in obese adults with type 2 diabetes mellitus as well as some features of the metabolic syndrome. Orlistat is generally well tolerated. Thus, orlistat is an option for the treatment of obese patients with or without type 2 diabetes and also has a role in the management of obese patients with the metabolic syndrome, associated comorbidities or concomitant disorders.

DrugBank Data that Cites this Article

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Orlistat	Pancreatic triacylglycerol lipase	Protein	Humans	Yes	Inhibitor	Details